Innate Pharma (NASDAQ:IPHA) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.16) by 50 percent. This is a 14.29 percent increase over losses of $(0.28) per share from the same period last year. The company reported quarterly sales of $6.583 million which missed the analyst consensus estimate of $9.100 million by 27.66 percent. This is a 19.47 percent increase over sales of $5.510 million the same period last year.